TerminatedPHASE2, PHASE3NCT04566484
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
Studying Chikungunya
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- International Vaccine Institute
- Principal Investigator
- Sushant Sahastrabuddhe, MBBS, MPHDirector, Chikungunya Program,International Vaccine Institute
- Intervention
- BBV87 Chikungunya vaccine(drug)
- Enrollment
- 3210 enrolled
- Eligibility
- 12-65 years · All sexes
- Timeline
- 2021 – 2025
Study locations (7)
- Clínica de la Costa, Barranquilla, Atlántico, Colombia
- Centro de Atención en Investigación Médica (CAIMED)., Yopal, Casanare Department, Colombia
- Centro de Atencion y Diagnostico de Enfermedades Infecciosas (CDI)., Bucaramanga, Santander Department, Colombia
- Clínica San Agustín, San José, Costa Rica
- Centro de Estudios Clínicos Salud Avanzada. (CECLISA), Guatemala City, Guatemala
- Centro de Vacunacion Internacional S.A. CEVAXIN, Panama City, Panama
- Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04566484 on ClinicalTrials.govOther trials for Chikungunya
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07555392A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Bharat Biotech International Limited
- ENROLLING BY INVITATIONNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ACTIVE NOT RECRUITINGNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07520279Xpert® Tropical Fever Test on GeneXpert® Edge X SystemCepheid
- ACTIVE NOT RECRUITINGNCT06651372The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return TravelersUniversity Hospital, Strasbourg, France
- RECRUITINGNCT07120724Real-World Study on Chinese Medicine for Treating Chikungunya FeverGuangzhou University of Traditional Chinese Medicine
- RECRUITINGPHASE3NCT07003984A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Bavarian Nordic